Fortrea’s shares rallied 27.7% following the quarter as improving commercial traction, diversification into biotech, and operational milestones notably exceeded investor expectations.

• Achieved a Q1 book-to-bill ratio of 1.15x, marking the third consecutive quarter above 1.1x and signaling strong commercial execution.
• Biotech segment saw significant year-over-year authorization growth, driven by new client wins and increased RFP activity from early-stage and innovative therapeutic companies.
• Strong double-digit pipeline growth and strategic client wins in China complement a diversified global footprint with over 1,000 employees in the region.
• Launched Fortrea Intelligent Technology (FIT), an AI-powered workflow automation suite, receiving immediate positive market and customer feedback, enhancing operational differentiation.
• Clinical pharmacology unit delivered its first-in-human dosing for a rare blood disorder, underscoring capability expansion beyond standard trials.